Alnylam Pharmaceuticals Stock Z Score
ALNY Stock | USD 145.32 1.40 0.95% |
Alnylam | Z Score |
Alnylam Pharmaceuticals Company Z Score Analysis
Alnylam Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Alnylam Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Alnylam Pharmaceuticals is extremely important. It helps to project a fair market value of Alnylam Stock properly, considering its historical fundamentals such as Z Score. Since Alnylam Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alnylam Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alnylam Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
In accordance with the company's disclosures, Alnylam Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Alnylam Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Alnylam Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alnylam Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alnylam Pharmaceuticals' value.Shares | Jpmorgan Chase & Co | 2023-12-31 | 3 M | Capital Research Global Investors | 2023-12-31 | 2.9 M | Norges Bank | 2023-12-31 | 2 M | Geode Capital Management, Llc | 2023-12-31 | 1.9 M | Rtw Investments, Llc | 2023-12-31 | 1.6 M | Venbio Select Advisor Llc | 2023-12-31 | 1.1 M | Legal & General Group Plc | 2023-12-31 | 930.9 K | Pictet Asset Manangement Sa | 2023-12-31 | 885.6 K | Bellevue Group Ag | 2023-12-31 | 885.3 K | Capital World Investors | 2023-12-31 | 16.2 M | Vanguard Group Inc | 2023-12-31 | 11.9 M |
Alnylam Fundamentals
Return On Equity | -15.01 | ||||
Return On Asset | -0.0478 | ||||
Profit Margin | (0.24) % | ||||
Operating Margin | (0.26) % | ||||
Current Valuation | 18.72 B | ||||
Shares Outstanding | 126.45 M | ||||
Shares Owned By Insiders | 0.41 % | ||||
Shares Owned By Institutions | 95.02 % | ||||
Number Of Shares Shorted | 2.8 M | ||||
Price To Earning | (22.92) X | ||||
Price To Book | 142.92 X | ||||
Price To Sales | 10.27 X | ||||
Revenue | 1.83 B | ||||
Gross Profit | 868.6 M | ||||
EBITDA | (228.12 M) | ||||
Net Income | (440.24 M) | ||||
Cash And Equivalents | 2.27 B | ||||
Cash Per Share | 18.41 X | ||||
Total Debt | 2.68 B | ||||
Debt To Equity | 5.63 % | ||||
Current Ratio | 3.48 X | ||||
Book Value Per Share | (1.75) X | ||||
Cash Flow From Operations | 104.16 M | ||||
Short Ratio | 3.86 X | ||||
Earnings Per Share | (3.53) X | ||||
Price To Earnings To Growth | (0.49) X | ||||
Target Price | 222.68 | ||||
Number Of Employees | 2.1 K | ||||
Beta | 0.4 | ||||
Market Capitalization | 18.55 B | ||||
Total Asset | 3.83 B | ||||
Retained Earnings | (7.01 B) | ||||
Working Capital | 2.01 B | ||||
Current Asset | 1.11 B | ||||
Current Liabilities | 62.1 M | ||||
Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alnylam Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Alnylam Stock
0.78 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
0.77 | JSPRW | Jasper Therapeutics | PairCorr |
0.73 | MRSN | Mersana Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.64 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
0.63 | INZY | Inozyme PharmaInc Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alnylam Pharmaceuticals Piotroski F Score and Alnylam Pharmaceuticals Valuation analysis. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.53) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.